Professors debate functionality

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Professors debate functionality

Annual Meeting attendees flocked to a bustling session about recent developments relating to the doctrine of trademark functionality yesterday

The panel included Professors Mark Lemley of Stanford Law School, Dan Burke of the University of California, Irvine School of Law and Eric Goldman of Santa Clara University School of Law.

Moderator Susan Montgomery of Northeastern University focused on two key cases—Rosetta Stone v. Google and Fleischer Studios Inc. v. A.V.E.L.A—in which two separate courts ruled in part that the trademarks at issue in each case were functional, and therefore unprotectable.

Both cases are on appeal and being closely watched by INTA (which has filed amicus briefs in each case) and the trademark community. “Betty Boop is outrageous and will spell the death knell for trademarks [if not reversed],” said one audience member.

The panel of professors disagreed and said that the case law is not clear that trademark rights guarantee a merchandising right, which generated lively commentary from the audience.      

more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Palińska is the business & IP law lead at CD Projekt Red in Poland
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Schwitulla is the head of litigation management at Nokia in Germany
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article